Compare SUVEN LIFE with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES TORRENT PHARMA SUVEN LIFESCIENCES/
TORRENT PHARMA
 
P/E (TTM) x 19.7 58.9 33.4% View Chart
P/BV x 4.0 6.2 63.9% View Chart
Dividend Yield % 0.5 0.8 64.4%  

Financials

 SUVEN LIFESCIENCES   TORRENT PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
TORRENT PHARMA
Mar-18
SUVEN LIFESCIENCES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3381,550 21.8%   
Low Rs1691,144 14.8%   
Sales per share (Unadj.) Rs52.1354.7 14.7%  
Earnings per share (Unadj.) Rs6.840.1 17.0%  
Cash flow per share (Unadj.) Rs8.664.2 13.3%  
Dividends per share (Unadj.) Rs1.5014.00 10.7%  
Dividend yield (eoy) %0.61.0 56.9%  
Book value per share (Unadj.) Rs65.3273.1 23.9%  
Shares outstanding (eoy) m127.28169.22 75.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.8 128.1%   
Avg P/E ratio x37.133.6 110.5%  
P/CF ratio (eoy) x29.621.0 141.1%  
Price / Book Value ratio x3.94.9 78.8%  
Dividend payout %22.034.9 62.9%   
Avg Mkt Cap Rs m32,272227,897 14.2%   
No. of employees `0001.114.7 7.4%   
Total wages/salary Rs m66111,353 5.8%   
Avg. sales/employee Rs Th6,132.24,083.0 150.2%   
Avg. wages/employee Rs Th611.1772.3 79.1%   
Avg. net profit/employee Rs Th803.5461.3 174.2%   
INCOME DATA
Net Sales Rs m6,63560,021 11.1%  
Other income Rs m2422,988 8.1%   
Total revenues Rs m6,87763,009 10.9%   
Gross profit Rs m1,60413,493 11.9%  
Depreciation Rs m2214,086 5.4%   
Interest Rs m383,085 1.2%   
Profit before tax Rs m1,5879,310 17.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7182,529 28.4%   
Profit after tax Rs m8696,781 12.8%  
Gross profit margin %24.222.5 107.6%  
Effective tax rate %45.227.2 166.5%   
Net profit margin %13.111.3 116.0%  
BALANCE SHEET DATA
Current assets Rs m6,23252,623 11.8%   
Current liabilities Rs m1,49052,022 2.9%   
Net working cap to sales %71.51.0 7,131.7%  
Current ratio x4.21.0 413.5%  
Inventory Days Days86120 72.3%  
Debtors Days Days8376 108.4%  
Net fixed assets Rs m4,04385,016 4.8%   
Share capital Rs m127846 15.0%   
"Free" reserves Rs m8,18345,376 18.0%   
Net worth Rs m8,31046,222 18.0%   
Long term debt Rs m1841,115 0.0%   
Total assets Rs m10,389142,432 7.3%  
Interest coverage x43.14.0 1,072.8%   
Debt to equity ratio x00.9 0.2%  
Sales to assets ratio x0.60.4 151.6%   
Return on assets %8.76.9 126.1%  
Return on equity %10.514.7 71.3%  
Return on capital %19.514.2 137.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62214,580 38.6%   
Fx outflow Rs m1,7993,600 50.0%   
Net fx Rs m3,82210,980 34.8%   
CASH FLOW
From Operations Rs m3568,942 4.0%  
From Investments Rs m-279-47,070 0.6%  
From Financial Activity Rs m-22534,174 -0.7%  
Net Cashflow Rs m-148-3,655 4.1%  

Share Holding

Indian Promoters % 63.4 71.5 88.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.0 -  
FIIs % 0.0 12.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 8.8 414.8%  
Shareholders   37,287 26,511 140.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 19, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - PIRAMAL ENTERPRISES COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS